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Abstract
Atypical antipsychotics show preferential 5-HT2A versus dop-
amine (DA) D2 receptor affinity. At clinical doses, they fully
occupy cortical 5-HT2 receptors, which suggests a strong
relationship with their therapeutic action. Half of the pyramidal
neurones in the medial prefrontal cortex (mPFC) express
5-HT2A receptors. Also, neurones excited through 5-HT2A
receptors project to the ventral tegmental area (VTA). We
therefore hypothesized that prefrontal 5-HT2A receptors can
modulate DA transmission through excitatory mPFC–VTA
inputs. In this study we used single unit recordings to examine
the responses of DA neurones to local (in the mPFC)
and systemic administration of the 5-HT2A/2C agonist 1-[2,5-
dimethoxy-4-iodophenyl-2-aminopropane] (DOI). Likewise,
using microdialysis, we examined DA release in the mPFC
and VTA (single/dual probe) in response to prefrontal and
systemic drug administration. The local (in the mPFC) and
systemic administration of DOI increased the firing rate
and burst firing of DA neurones and DA release in the VTA
and mPFC. The increase in VTA DA release was mimicked by
the electrical stimulation of the mPFC. The effects of DOI
were reversed by M100907 and ritanserin. These results
indicate that the activity of VTA DA neurones is under the
excitatory control of 5-HT2A receptors in the mPFC. These
observations may help in the understanding of the therapeutic
action of atypical antipsychotics.
Keywords: atypical antipsychotics, dopamine, prefrontal
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The ventral tegmental area (VTA) gives rise to the mesocor-
tical and mesolimbic dopamine (DA) systems, which are
involved in cognition, memory, reward and behavioural
control (Glowinski et al. 1984; Williams and Goldman-
Rakic 1995; Robbins 2000; Tzschentke and Schmidt 2000;
Schultz 2004). Psychotic and cognitive/negative symptoms
in schizophrenia appear to be associated with an overactivity
of the mesolimbic pathway and a hypofunction of the
mesocortical pathway, respectively (Carlsson 1988; Wein-
berger et al. 1994; Laruelle et al. 1996; Abi-Dargham et al.
2000).
The activity of DA and non-DA neurones in the VTA is
modulated, among other areas, by the medial prefrontal
cortex (mPFC) (Thierry et al. 1979, 1983; Tong et al. 1996,
1998; Carr and Sesack 2000a,b). This control is exerted via
direct excitatory afferents as well as indirectly through the
laterodorsal/pedunculopontine tegmentum or the nucleus
accumbens/ventral pallidum pathways (Tzschentke and
Schmidt 2000; Floresco et al. 2003; Adell and Artigas
2004; Omelchenko and Sesack 2005). The prefrontal cortex
(PFC) plays a key role in higher brain functions (Fuster
2001) and prefrontal function and metabolism is altered in
patients with schizophrenia (Weinberger et al. 1994;
Andreasen et al. 1997). Likewise, cognitive deﬁcits in
schizophrenic patients are mediated by disruptions in brain
circuits involving the PFC (Bertolino et al. 2000).
Classical neuroleptics used to treat schizophrenia block
DA D2 receptors (Seeman and Lee 1975; Creese et al. 1976),
an action which also evokes extrapyramidal motor symptoms
and hyperprolactinaemia. With few exceptions (e.g. amisul-
pride) second generation (atypical) antipsychotics display a
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preferential 5-HT2 versus DA D2 receptor afﬁnity and
occupancy in brain (Nyberg et al. 1998; Meltzer 1999)
although ‘atypicality’ may encompass more than one mech-
anism (Roth et al. 2003). Several previous studies have
reported that the administration of 5-HT2A receptor ligands
such as DOI (5-HT2A/2C receptor agonist) or M100907
(selective 5-HT2A receptor antagonist) modulates the DA
system (Gobert and Millan 1999; Ichikawa et al. 2001a;
Minabe et al. 2001; Pehek et al. 2001; Porras et al. 2002).
However, the location of 5-HT2A receptors involved in these
effects is presently unknown.
The neocortex of the rodent, primate and human brain
contains 5-HT2A receptors, with an enrichment in frontal
regions (Pompeiano et al. 1994; Burnet et al. 1995; Lo´pez-
Gime´nez et al. 1998; Amargo´s-Bosch et al. 2004). Recent
data indicate that a large population (50–66%) of pyramidal
neurones and a smaller proportion of GABA interneurones
(20%) in the rat mPFC, an area projecting densely to the
VTA, express 5-HT2A receptors (Santana et al. 2004).
Consistent with this dual location, 5-HT2A receptor activa-
tion depolarizes or hyperpolarizes pyramidal neurones
depending on experimental conditions (Araneda and And-
rade 1991; Tanaka and North 1993).
In a previous study, we noticed that pyramidal neurones in
the mPFC excited through the activation of 5-HT2A receptors
project to the VTA, as assessed by antidromic stimulation
(Puig et al. 2003). Likewise, the 5-HT2A/2C agonist DOI
markedly enhanced the activity of pyramidal neurones in the
mPFC, including those projecting to the VTA (Puig et al.
2003). This raised the possibility that the aforementioned
effects of 5-HT2A receptor ligands on VTA DA neurones are
mediated by the activation of such receptors in the mPFC,
thereby affecting the activity of pyramidal neurones in the
mPFC projecting to the VTA.
Hence, we conducted the present study to speciﬁcally
assess whether 5-HT2A receptors in the mPFC modulate the
activity of DA neurones in the VTA and the release of DA in
the mesocortical pathway.
Materials and methods
Animals and treatments
Male albino Wistar rats (230–300 g; Iffa Credo, Lyon, France) were
kept in a controlled environment (12 h light/dark cycle and
22 ± 2C room temperature) with food and water provided
ad libitum. Animal care followed the European Union regulations
(O.J. of E.C. L358/1 18/12/1986) and was approved by the
Institutional Animal Care and Use Committee. Stereotaxic coordi-
nates (in mm) were taken from bregma and duramater using the atlas
of Paxinos and Watson (1998).
All drugs were from Sigma/RBI (Natick, MA, USA) except
M100907 which was from Eli Lilly and Co. Indianapolis, IN, USA
(LY 368675). For the assessment of local or distal effects in
microdialysis experiments, drugs were dissolved in the perfusion
ﬂuid or water (except M1009007 which was dissolved in acetic
acid) and diluted to appropriate concentrations in artiﬁcial CSF
(aCSF). Concentrated solutions (pH adjusted to 6.5–7.4 with
NaHCO3 when necessary) were stored at )80C and working
solutions were prepared daily by dilution in aCSF at the stated
concentrations and were applied by reverse dialysis (uncorrected for
drug recovery). Control rats were perfused with aCSF. The bars in
the ﬁgures show the period of drug application (corrected for the
void volume of the system). Typically, the ﬁnal concentrations of
compounds used in microdialysis experiments were: DOI, MK-801
and ritanserin, 300 lM; bicuculline, 10, 30 and 100 lM; M100907,
30, 100 and 300 lM and tetrodotoxin, 1 lM.
For recordings of VTA DA neurones, drugs were administered
i.v. or applied through a stereotaxically implanted cannula in the
mPFC (tip coordinates: AP, +3.2; L, )0.8; DV, )3.5) following a
described procedure (Martı´n-Ruiz et al. 2001). Brieﬂy, 40 pmol of
DOI (0.2 lL, 200 lM, dissolved in aCSF) was applied through a
32g stainless steel cannula (Small Parts Inc., Miami, FL, USA). The
cannula was attached to a 10-lL Hamilton syringe by a Teﬂon
tubing. A microinfusion pump (Bioanalytical Systems Inc., West
Lafayette, IN, USA) was used. After a baseline recording of at least
5 min, DOI was infused over the course of 1 min. Depending on the
effect obtained, a second DOI infusion was administered 5 min later.
In all experiments, only one neurone per rat was recorded. After
experimental procedures were completed, animals were killed by an
overdose of anaesthetic and a careful histological veriﬁcation of the
correctness of the implants was carried out.
Single unit recordings of dopamine neurones in ventral
tegmental area
Two sets of experiments were performed to examine the responses
of VTA DA neurones to the local (in the mPFC) and systemic
administration of DOI. Rats were anaesthetized (chloral hydrate
400 mg/kg i.p.) and positioned in a David Kopf stereotaxic frame.
Thereafter, chloral hydrate was continuously administered i.p. at a
dose of 50–70 mg/kgÆh using a perfusion pump to avoid ﬂuctuations
in the degree of anaesthesia that can affect the activity of DA
neurones (Fa et al. 2003). Body temperature was maintained at
37C with a heating pad. DA neurones were recorded extracellularly
with glass micropipettes pulled from 2.0-mm capillary glass (WPI,
Sarasota, FL, USA) on a Narishige PE-2 pipette puller (Narishige
Scientiﬁc Instruments Lab, Tokyo, Japan). Microelectrodes were
ﬁlled with 2 M NaCl. Typically, impedance was 4–10 MW. Single
unit extracellular recordings were ampliﬁed with a Neurodata IR283
(Cygnus Technology Inc., Delaware Water Gap, PA, USA), post-
ampliﬁed and ﬁltered with an ampliﬁer (Cibertec, Madrid, Spain)
and computed on-line using a DAT 1401 plus interface system
Spike2 software (Cambridge Electronic Design, Cambridge, UK).
Descents in the VTA were carried out at AP, )5.0 to )5.6; L,
)0.5 to )1 and DV, )7.5 to )9.0 to record DA neurones in both the
parabrachial and paranigral subdivisions. The identiﬁcation of DA
neurones and burst ﬁring analysis were carried out according to the
criteria of Grace and Bunney (1984), as previously used by Celada
et al. (1999). Brieﬂy, neurones were considered dopaminergic if
they possessed the following characteristics: (1) action potential
duration greater than 2.5 ms; (2) typical bi- or triphasic waveform
often with a notch in the initial rising phase; (3) slow ﬁring rate
(recorded neurones ﬁred at 1–7 spikes/s) and (4) frequent presence
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of bursts. The structure of bursts was deﬁned as starting with a ﬁrst
interspike interval of <80 ms and ending with an interspike interval
of 160 ms or greater (Grace and Bunney 1984). Recorded neurones
had 10–11% of spikes ﬁred in bursts during baseline conditions
(Tables 1 and 2). When appropriate, additional pharmacological
identiﬁcation was carried out with i.v. apomorphine followed by
haloperidol reversal.
Microdialysis procedures
Microdialysis experiments in the mPFC were conducted essentially
as described previously (Martı´n-Ruiz et al. 2001). Rats were
anaesthetized with sodium pentobarbital (60 mg/kg i.p.) and
implanted with 4-mm concentric dialysis probes (Cuprophan) in
the mPFC at AP, +3.2; L, )0.8 and DV, )6.0. Groups of rats were
also implanted with a second microdialysis probe (tip 1.5 mm) in
the VTA (coordinates: AP, )5.3; L, )2.1 and DV, )8.9 with a
vertical angle of 10 which placed the probe tip at L, )0.6 and DV,
)8.7). Microdialysis experiments were performed in freely-moving
rats >20 h after surgery except in experiments involving the
electrical stimulation of the mPFC (see below). Probes were
perfused with aCSF pumped at 1.5 lL/min. Following an initial
100-min stabilization period, four baseline samples were collected
(20 min each) before local (reverse dialysis) or systemic drug
administration and then successive dialysate samples were collected.
In most experiments, the 5-HT2A/2C agonist DOI was locally
perfused alone for six fractions followed by its application in
combination with other drugs for another six fractions.
In the experiments examining the effects of the electrical
stimulation of the mPFC on DA release in the VTA, rats were
anaesthetized with chloral hydrate and 10-min fractions were
collected (ﬂow rate 3.0 lL/min). Bipolar stimulating electrodes
consisted of two stainless steel enamel-coated wires (California Fine
Wire, Grover Beach, CA, USA) with a diameter of 150 lm and a tip
separation of 200 lm and in vitro impedances of 10–30 KW. A
stimulating electrode was stereotaxically implanted in the mPFC
(AP, )3.2; L, )0.8 and DV, )3.0) and secured to the skull with glue
and dental cement. Constant current electrical stimuli were
generated with a Grass stimulation unit S-48 connected to a Grass
SIU 5 stimulus isolation unit. Three stimulating conditions were
used: S1 (0.9 Hz, 1.5 mA, 0.2 ms), S2 (10 Hz, 0.5 mA, 1 ms) and
S3 (20 Hz, 0.5 mA, 1 ms) (Celada et al. 2001).
The concentration of DA in dialysate samples was determined
by HPLC with amperometric detection, using a modiﬁcation of
a previously described method (Ferre´ et al. 1994). Brain dialy-
sates were collected on microvials containing 5 lL of 10 mM
perchloric acid and were rapidly injected into the HPLC. DA was
Table 1 Effect of the local application of
DOI in the medial prefrontal cortex (mPFC)
on dopamine cell firing in the ventral teg-
mental area
All neurones DOI-sensitive neurones
Baseline DOI Baseline DOI
Firing rate (Hz) 3.17 ± 0.26 3.70 ± 0.32** 3.44 ± 0.34 4.30 ± 0.39**
% of basal firing rate 100 119 ± 7* 100 132 ± 9**
% spikes in burst 10.0 ± 2.3 23.0 ± 3.9** 13.1 ± 3.2 32.5 ± 4.5**
No. of spikes per burst 2.5 ± 0.1 (24) 2.9 ± 0.1(27)** 2.6 ± 0.1 (17) 3.2 ± 0.1(19)**
No. of bursts in 3 min 24 ± 6 56 ± 12** 31 ± 8 80 ± 15**
Spikes in burst in 3 min 67 ± 22 192 ± 46** 89 ± 31 281 ± 61**
N 29 29 19 19
Data are from 29 or 19 neurones, except values shown in parentheses (some neurones did not
exhibit basal burst firing).Values are the maximal effect (average of 3 min) produced by the
application of DOI in the mPFC. *p < 0.01, **p < 0.005 vs. pre-drug values, paired Student’s t-test.
Table 2 Effect of the systemic administra-
tion of DOI on dopamine cell firing in the
ventral tegmental area
Baseline
DOI
(50 lg/kg)
DOI
(100 lg/kg)
M100907
(250–500 lg/kg)
Firing rate (Hz) 3.38 ± 0.49 3.64 ± 0.41 4.04 ± 0.47* 1.72 ± 0.48**,*
% of basal firing rate 100 115 ± 7 128 ± 9* 56.1 ± 8.1**,*
% spikes in burst 10.9 ± 4.0 16.4 ± 4.5 22.5 ± 6.1* 0.86 ± 0.86***
No. of spikes per burst 2.3 ± 0.1 2.3 ± 0.1 2.7 ± 0.2* 2(1)
No. of burst in 3 min 30 ± 13 46 ± 15 60 ± 18* 0.8 ± 0.8**
Spikes in burst in 3 min 79 ± 38 115 ± 41 178 ± 57* 2 ± 2**
N 12 12 12 5
Values are the effect of DOI or M100907 at the specified i.v. dose measured during 3 min.
Repeated measures ANOVA showed a significant effect of DOI on all variables examined (*p < 0.05
vs. baseline, Duncan test following repeated measures ANOVA). The effect of M100907 was
examined in a subgroup of five neurones activated by DOI. Only one neurone showed burst firing
after M100907 administration. **p < 0.05 vs. DOI, ***p ¼ 0.07 vs. DOI and baseline, paired Stu-
dent’s t-test.
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amperometrically detected at 5–7.5 min with a limit of detection of
3 fmol/sample using an oxidation potential of +0.75 V.
Data and statistical analysis
Changes in ﬁring rate or the proportion of burst ﬁring in DA
neurones were assessed using repeated measures ANOVA or paired
Student’s t-tests, as appropriate. These values were quantiﬁed by
averaging the values during 3 min after local or i.v. administration
(omitting the ﬁrst minute).
Microdialysis results are expressed as fmol/fraction (uncorrected
for recovery) and shown in ﬁgures as percentages of basal values
(individual means of four pre-drug fractions). Statistical analysis
was carried out using one- or two-way ANOVA for repeated measures
of the DA values during speciﬁed periods followed by post-hoc
t-test when appropriate. Typically, the effect of DOI was assessed by
one-way repeated measures ANOVA comparing baseline DA values
with those attained during DOI perfusion. The effect of drugs on the
DOI-induced DA elevation was assessed with one-way repeated
measures ANOVA comparing DA values during DOI infusion with
those attained during the infusion of DOI plus test drug. The
p-values shown in the Results correspond to the time effect in the
case of one-way repeated measures ANOVA and to the time–treatment
interaction for two-way repeated measures ANOVA (e.g. stimulated
vs. control rats). Data are expressed as the mean ± SEM. Statistical
signiﬁcance has been set at the 95% conﬁdence level (two tailed).
Results
Electrical and pharmacological stimulation of the medial
prefrontal cortex–ventral tegmental area pathway.
Effects on dopamine release
Baseline extracellular DA values in the VTA of chloral
hydrate-anaesthetized rats was 8 ± 1 fmol/10-min sample
(n ¼ 24). In freely-moving rats, the corresponding baseline
concentrations in the VTA and mPFC (20-min fractions)
were 19 ± 1 and 15 ± 1 fmol/20-min fraction (n ¼ 49 and
79, respectively).
We examined the effect of the electrical stimulation of the
mPFC on extracellular DA concentration in the ipsilateral
VTA. Control (sham) rats in these experiments were equally
implanted with stimulation electrodes in the mPFC but no
current was passed. In a ﬁrst experiment, the electrical
stimulation of the mPFC at low frequency (S1; see Materials
and methods) did not increase the extracellular DA concen-
tration in the VTA. Higher stimulation frequencies (10 and
20 Hz; S2 and S3 conditions) signiﬁcantly elevated the DA
release in the VTA to 145 ± 12% (n ¼ 5; F17,68 ¼ 6.20;
p < 0.0001; one-way repeated measures ANOVA; data not
shown). In a second experiment (Fig. 1a), the stimulation at
S2 and S3 conditions also signiﬁcantly elevated extracellular
DA compared with sham-stimulated rats, reaching a level
similar to that seen in the previous experiment (153 ± 18%;
n ¼ 7 for stimulated rats, n ¼ 6 for sham controls; F1,11 ¼
16.90, p < 0.0015 group effect; F21,231 ¼ 4.38, p < 0.00001
time effect; F21,231 ¼ 2.70 p < 0.0015 time–group
interaction; two-way repeated measures ANOVA). This effect
was completely prevented by the local perfusion of the
NMDA receptor antagonist MK-801 (300 lM) in the VTA
(n ¼ 6; F1,11 ¼ 11.81, p < 0.0005 group effect; F21,231 ¼
2.94, p < 0.0001 time effect; F21,231 ¼ 3.86, p < 0.0001
time–group interaction; two-way repeated measures ANOVA).
To examine the effect of the pharmacological stimulation
of the mPFC, another group of rats was implanted with two
microdialysis probes (mPFC and VTA). After collection of
baseline values, the GABAA antagonist bicuculline was
perfused in the mPFC at increasing concentrations (10, 30
and 100 lM; 100 min each) in order to disinhibit pyramidal
neurones from local tonic GABAergic inputs and to increase
the excitatory output to the VTA. Following bicuculline
infusion in the mPFC, DA release was signiﬁcantly elevated
in both areas, reaching 269 ± 50% of baseline in the mPFC
Fig. 1 (a) The electrical stimulation of the medial prefrontal cortex
(mPFC) for 10-min periods at S2 and S3 conditions (S2, 10 Hz, 1 ms,
0.5 mA; S3, 20 Hz, 1 ms, 0.5 mA) significantly increased the dop-
amine (DA) release in the ventral tegmental area (VTA). This effect
persisted until the end of the collection period (70 min after the end of
S3) and was prevented by the perfusion of MK-801 (300 lM) admin-
istered by reverse dialysis in the VTA (n ¼ 6, sham; n ¼ 7, stimula-
tion; n ¼ 6, stimulation + MK-801). (b) Effect of the local application in
the mPFC of the GABAA receptor antagonist bicuculline (10, 30 and
100 lM, shown by horizontal bars) on DA release in the mPFC and
VTA (n ¼ 6). See text for statistical analysis.
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(n ¼ 6; F18,90 ¼ 6.59; p < 0.00001 vs. baseline, one-way
repeated measures ANOVA) and 201 ± 16% of baseline in the
VTA (F18,90 ¼ 6.02; p < 0.00001 vs. baseline, one-way
repeated measures ANOVA; Fig. 1b). Rats showed an increase
in motor activity at 30–100 lM bicuculline but no seizure
activity was observed.
In another dual-probe experiment, bicuculline application
in the VTA (30–100 lM, 120 min each) elevated DA release
locally (229 ± 25%; F15,175 ¼ 8.89, p < 0.00001 vs. base-
line, one-way repeated measures ANOVA) and in the mPFC
(167 ± 16%; F15,175 ¼ 8.63, p < 0.00001 vs. baseline, one-
way repeated measures ANOVA) (n ¼ 6; data not shown).
Notwithstanding observations supporting a noradrenergic
origin of the DA release in the PFC (Devoto et al. 2002)
these results agree with previous observations showing a
VTA dependence of cortical DA release (Mathe´ et al. 1999).
Effects of the activation of 5-HT2A receptors in medial
prefrontal cortex on dopamine neurone activity and
dopamine release
The application of DOI (0.2 lL, 40 pmol) in the mPFC
enhanced (>30%) the activity of 65% of the recorded DA
neurones in the VTA (19/29). The rest were unaffected (n ¼
9) or decreased (n ¼ 1). The application of aCSF in the
mPFC did not elevate burst ﬁring (n ¼ 4). Considering all
neurones, DOI signiﬁcantly increased DA activity (Table 1;
Fig. 2). On average, the percentage of spikes in bursts, the
total number of bursts and the total number of spikes ﬁred in
Fig. 2 (a) Representative example of a ventral tegmental area (VTA)
dopamine (DA) neurone whose burst firing was increased by the local
application of DOI in the medial prefrontal cortex (mPFC). Shown is
the integrated firing rate histogram (abcissa, spikes/10 s; ordinate,
min). The four upper traces show burst trains in baseline conditions,
after cortical DOI application (first and second doses) and after sys-
temic ritanserin (RIT) administration. This unit had a baseline 1% of
burst firing. The application of DOI (0.2 lL, 40 pmol, denoted by one
1-min horizontal bar) in the mPFC increased burst firing to 9 and 35%
(first and second applications). The administration of ritanserin
(1 + 1 mg/kg i.v.) reduced burst firing to 14%. (b) Example of a VTA
DA neurone insensitive to the application of DOI in the mPFC. The unit
activity was suppressed by the administration of apomorphine (APO;
36 lg/kg i.v.) and reversed by the subsequent administration of
haloperidol (HAL; 0.4 mg/kg i.v.). (c) In dual-probe microdialysis
experiments, application of DOI in the mPFC increased DA release in
the mPFC and VTA (n ¼ 8; d and m, respectively). Controls (n ¼ 4;
s and n) were perfused with artificial CSF (aCSF) for the entire
experiment. Inset: reversal by ritanserin (300 lM, applied in the mPFC)
of the elevation of DA release in the mPFC and VTA produced by the
application of DOI (300 lM) in the mPFC. (d) In single probe experi-
ments, the application of 300 lM DOI in the mPFC increased the local
DA release (d; n ¼ 9). This effect was reversed by co-perfusion of
1 lM tetrodotoxin (TTX, n ¼ 5; h) and the selective 5-HT2A receptor
antagonist M100907 (n ¼ 6; j). Controls (n ¼ 5; s) were perfused
with aCSF for the entire experiment. Horizontal bars show the time of
drug application (corrected for the void volume of the system). See text
and Table 1 for statistical analysis. **p < 0.001 vs. DOI alone. PFC,
prefrontal cortex.
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bursts were signiﬁcantly increased by DOI application in the
mPFC (n ¼ 29). This change was more marked and
signiﬁcant in the subgroup of neurones sensitive to DOI
(n ¼ 19; Table 1). Likewise, DOI slightly but signiﬁcantly
increased the overall ﬁring rate of DA neurones (to
119 ± 7% of baseline for all neurones, p < 0.01, and
132 ± 9% for DOI-sensitive neurones, p < 0.005; paired
Student’s t-test). The increase in burst ﬁring induced by DOI
in the mPFC was reversed by the systemic administration of
the 5-HT2A/2C antagonist ritanserin (1–2 mg/kg i.v.). In the
three neurones where reversal was attempted, ritanserin
reduced the number of spikes ﬁred in bursts (2 min) from
218 ± 37 to 36 ± 34 (n ¼ 3; p < 0.05; paired Student’s
t-test). Figure 2 shows representative examples of DA
neurones excited by the application of DOI in the mPFC
and reversed by ritanserin (Fig. 2a) and insensitive to DOI
(Fig. 2b).
In pilot microdialysis experiments, DOI was perfused in
the mPFC at increasing concentrations to examine whether it
could modulate the local DA release. The maximal effect
was attained at 300 lM (220 ± 12% of baseline; data not
shown) and this concentration was used subsequently. In rats
implanted with two microdialysis probes (in the mPFC and
VTA) the application of 300 lM DOI in the mPFC
signiﬁcantly increased DA release in both areas (n ¼ 8;
F15,105 ¼ 7.39 for the mPFC; F15,105 ¼ 12.43 for the VTA;
p < 0.00001 vs. baseline for both areas; one-way repeated
measures ANOVA; Fig. 2c). Maximal elevations in the mPFC
and VTA were 217 ± 32 and 163 ± 7% of baseline,
respectively. The co-perfusion of ritanserin (300 lM) in the
mPFC signiﬁcantly reversed the elevation produced by DOI
in both areas (n ¼ 5; F9,36 ¼ 7.23, p < 0.0001 vs. DOI
alone in the mPFC; F9,36 ¼ 7.57, p < 0.0001 vs. DOI alone
in the VTA, one-way repeated measures ANOVA; see inset in
Fig. 2c).
In single probe experiments, the application of DOI in the
mPFC increased the local DA release to a similar extent
(maximal effect 192 ± 14% of baseline, n ¼ 9; F15,120 ¼
9.20, p < 0.0001 vs. baseline, one-way repeated measures
ANOVA). The DA increase was reversed by the co-perfusion
of 1 lM tetrodotoxin (to 55 ± 13% of baseline; n ¼ 5;
F15,60 ¼ 2.38, p < 0.00001, one-way repeated measures
ANOVA; p < 0.05 DOI vs. baseline; p < 0.05 tetrodotoxin
vs. DOI; Duncan test post-ANOVA) and by the selective
5-HT2A receptor antagonist M100907 (300 lM, to 81 ± 10%
of baseline; n ¼ 6; F15,75 ¼ 8.71, p < 0.00001, one-way
repeated measures ANOVA; p < 0.05 DOI vs. baseline;
p < 0.05 M100907 vs. DOI; Duncan test post-ANOVA;
Fig. 2d). The increase in DA release produced by 300 lM
DOI was similar in awake and chloral hydrate-anaesthetized
rats (to 207 ± 32%; n ¼ 4; data not shown). The local
application of M100907 at 30, 100 and 300 lM (four
fractions each) by itself reduced DA release to 56 ± 7,
54 ± 4 and 37 ± 5% of baseline, respectively (n ¼ 5;
F15,60 ¼ 16.45, p < 0.0001 repeated measures ANOVA) (data
not shown).
Systemic administration of DOI. Effect on dopamine cell
firing and dopamine release
The i.v. administration of DOI (0.05–0.1 mg/kg) signiﬁ-
cantly increased the activity of DA neurones in the VTA
(n ¼ 12; F2,22 ¼ 5.90 for ﬁring rate; F2,22 ¼ 6.42 for burst
ﬁring; p < 0.01 vs. baseline; one-way repeated measures
ANOVA; Fig. 3a; Table 2). At the lower dose used, the effect
of DOI did not reach statistical signiﬁcance. However,
0.1 mg/kg i.v. signiﬁcantly increased the total ﬁring rate and
burst ﬁring. The latter effect was observed in terms of the
percentage of spikes ﬁred in bursts (from 10.9 ± 4.0 to
22.5 ± 6.1%) as well as the total number of bursts and the
number of spikes per burst (Table 2). In ﬁve out of six
neurones, the 5-HT2A receptor antagonist M100907 (0.25–
0.5 mg/kg i.v.) counteracted the effect of DOI on cell
ﬁring, reducing it to 56% of baseline (1.7 ± 0.5 vs. 3.1 ±
0.8 spikes/s, n ¼ 5; p < 0.05, paired Student’s t-test). Like-
wise, M100907 signiﬁcantly reversed the effect of DOI and
reduced the percentage of burst ﬁring at a dose not affecting
DA neurone activity in the VTA (Minabe et al. 2001). In
four out of ﬁve units, M100907 reduced the proportion of
burst ﬁring to below baseline, as in the example shown in
Fig. 3(a). The other neurone did not show baseline burst
ﬁring (Table 2).
These observations were paralleled by the corresponding
changes in DA release in microdialysis experiments. The
administration of DOI (0.5 mg/kg s.c.) signiﬁcantly
increased DA release in the VTA (n ¼ 4) (134 ± 5% of
baseline), an effect reversed by the subsequent adminis-
tration of 0.5 mg/kg s.c. M100907 (to 108 ± 9% of
baseline; n ¼ 4) (F15,45 ¼ 2.52, p < 0.01; repeated mea-
sures ANOVA; p < 0.05 DOI vs. baseline; p < 0.05
M100907 vs. DOI, non-signiﬁcant differences between
M100907 and baseline; post-hoc Duncan test; Fig. 3b).
Systemic M10097 administration did not change the DA
release by itself (Fig. 3c).
Likewise, in rats implanted with two microdialysis probes
(mPFC and VTA), the systemic administration of DOI
(0.5 mg/kg s.c.) signiﬁcantly increased DA release in both
areas (maximal effect 222 ± 23 and 158 ± 19% in the mPFC
and VTA, respectively; n ¼ 4; F11,33 ¼ 7.80, p < 0.00001
vs. baseline for the mPFC; F11,33 ¼ 4.41, p < 0.0005 vs.
baseline for the VTA, one-way repeated measures ANOVA;
Fig. 3c). This effect was prevented by the prior administra-
tion of M100097 (0.5 mg/kg s.c.) in both areas (n ¼ 4 in the
mPFC, n ¼ 3 in the VTA; F1,6 ¼ 12.86, p < 0.02 group
effect; F11,66 ¼ 4.67, p < 0.000001 time effect; F11,66 ¼
3.79, p < 0.0005 time–group interaction in the mPFC;
F1,5 ¼ 10.4, p < 0.025 group effect; F11,55 ¼ 2.94,
p < 0.005 time–group interaction in the VTA, two-way
repeated measures ANOVA; Fig. 3c).
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Discussion
The present results indicate that the activity of DA neurones
in the VTA and the release of DA in the VTA and mPFC are
modulated by 5-HT2A receptors in the mPFC. These
observations are consistent with the existence of anatomical
connections between the mPFC and VTA as well as the
excitatory role of 5-HT2A receptors on pyramidal cell activity
(see Introduction). Indeed, previous reports showed that high
frequency stimulation of the mPFC (e.g. 60 Hz) increased
DA release in nucleus accumbens (Taber and Fibiger 1995;
Jackson et al. 2001). To examine the effect of the mPFC on
VTA DA release, we used a lower, more physiological
frequency (10–20 Hz) to mimic the excitatory effect of DOI
on mPFC pyramidal neurones (Puig et al. 2003). The local
application of MK-801 in the VTA completely suppressed
the mPFC-evoked stimulation of DA release, supporting the
involvement of NMDA-dependent inputs. This observation
agrees with the fact that (1) mPFC stimulation induced burst
ﬁring in VTA DA neurones (Gariano and Groves 1988;
Murase et al. 1993; Tong et al. 1996); (2) this effect depends
on the activation of NMDA receptors (Overton and Clark
1997) and (3) burst ﬁring is associated with a greater DA
release (Chergui et al. 1994). Likewise, the elevation in VTA
DA release induced by bicuculline application in the mPFC
agrees with the notion that an increased mPFC activity
increases that of DA neurones (Murase et al. 1993).
Conceivably, bicuculline blocked (at least partially) local
GABAA inputs onto pyramidal neurones, thus increasing
their ﬁring activity and therefore the impulse ﬂow through
axons projecting to midbrain.
Various brain areas are involved in the control of the
activity of VTA DA neurones (Fig. 4). The present results
cannot establish whether the increased DA release in the
VTA produced by electrical stimulation of the mPFC is due
to the activation of a direct mPFC–VTA pathway or whether
long loops are also involved. In support of the ﬁrst possibility
are the observations that the PFC projects densely to the VTA
and PFC stimulation induced short-latency excitations in
VTA DA neurones (Thierry et al. 1979; Carr and Sesack
2000a).
A second possibility is that mPFC stimulation can also
increase DA release in the VTA via afferents to other brain
areas that in turn project and modulate the activity of VTA
neurones (Tzschentke and Schmidt 2000; Sesack et al. 2003;
Adell and Artigas 2004). Among these inputs the
PFC ﬁ laterodorsal/pedunculopontine tegmentum ﬁ VTA
and PFC ﬁ nucleus accumbens ﬁ ventral pallidum ﬁ
VTA pathways may be responsible (Fig. 4). Both pathways
have been shown to modulate DA neurone activity via phasic
and tonic inputs, respectively (Floresco et al. 2003). These
indirect pathways may perhaps account for the complex
biphasic responses of DA neurones to mPFC stimulation
(Tong et al. 1996).
Fig. 3 (a) Representative example of a ventral tegmental area (VTA)
dopamine (DA) neurone whose burst firing was increased by the i.v.
administration of DOI. Shown is the integrated firing rate histogram
(abcissa, spikes/10 s; ordinate, time in min). The four upper traces
show burst trains in baseline conditions, after DOI application (0.05
and 0.1 mg/kg, injections shown by vertical arrows) and after systemic
M100907 administration. This unit had a baseline 9% of burst firing,
which was increased to 35 and 31% after the first and second doses of
DOI. The administration of M100907 (250 lg/kg i.v.) reduced the
overall firing rate and completely suppressed the increase in burst
firing induced by DOI (to 4%). (b) The subcutaneous administration of
DOI (0.5 mg/kg) increased DA release in the VTA, an effect reversed
by M100907 administration (0.5 mg/kg s.c.) (n ¼ 4). A vehicle injec-
tion did not alter the increase in DA release produced by DOI (n ¼ 4).
(c) Likewise, in rats implanted with two microdialysis probes, the
administration of M100907 (0.5 mg/kg s.c.) before DOI (0.5 mg/kg
s.c.) prevented the increase in DA release produced by this agent in
the medial prefrontal cortex and VTA (n ¼ 4, vehicle + DOI; n ¼ 4,
M100907 + DOI; n ¼ 4, M100907 + vehicle, in both areas). Arrows
show the time of drug administration (first arrow, vehicle or M100907;
second arrow, vehicle or DOI). See text and Table 2 for statistical
analysis. APO, apomorphine; HAL, haloperidol.
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The application of DOI in the mPFC increased the activity
of VTA DA neurones, indicating that the activation of
5-HT2A/2C receptors in the mPFC modulates the activity of a
substantial proportion of VTA neurones (19 out of 29 DA
neurones were sensitive to DOI). Detailed tracing studies
have revealed a dense innervation of the VTA by the mPFC
(Carr and Sesack 2000a,b), which is consistent with the
present data. A relatively small proportion of DA neurones
projects back to the mPFC, closing the mesocortical VTA–
mPFC circuit, whereas the rest project to subcortical areas
other than nucleus accumbens as mesoaccumbal DA neurones
do not appear to be innervated by mPFC afferents (Carr and
Sesack 2000a). Hence, it is likely that DOI-sensitive neurones
project to limbic areas in addition to the mPFC, which
emphasizes the need for further work to examine the role of
prefrontal 5-HT2A receptors on DA release in limbic areas.
The increased dopaminergic activity was accompanied by
an increase in local (in the mPFC) and distal (in the VTA)
DA release when DOI was applied by reversed dialysis in the
mPFC. These effects were reversed by the co-perfusion of
the non-selective and selective 5-HT2A receptor antagonists
ritanserin and M100907, respectively, and by tetrodotoxin.
These results suggest that DOI increased the activity of the
mesocortical DA pathway and the terminal and somatodend-
ritic DA release through an impulse-dependent mechanism.
Likewise, the reversal of the action of DOI on mPFC DA
release by M100907 supports this effect being due to the
activation of 5-HT2A receptors. However, as DOI is also a
5-HT2C receptor agonist, the involvement of the latter
receptor cannot be fully discarded (see below).
Similarly, the systemic administration of DOI increased
DA neurone activity and DA release. Previous reports also
observed a similar effect of systemic DOI on prefrontal DA
release (Gobert and Millan 1999; Pehek et al. 2001).
However, to our knowledge, the systemic effect of DOI on
DA cell ﬁring and DA release in the VTA has not been
examined before. The enhanced burst ﬁring produced by
DOI was accompanied by an enhanced DA release in the
mPFC and VTA, an effect blocked by M100907.
Interestingly, 5-HT2A receptors involved in the effect of
DOI may be tonically activated as M100907 reduced the
ﬁring rate of some DA neurones to below baseline (Fig. 3a).
However, this possibility needs to be examined in more detail
as local (but not systemic) M100907 administration reduced
DA release in the mPFC (Pehek et al. 2001; this work).
Unfortunately, the limited availability of M100907 prevented
us from examining its effect on VTA cell ﬁring when given
alone.
mPFC
mPFC
mPFC + limbic areas
VTA
Glu
ACh PPTg
DOI
5-HT2A
5-HT1A
iGlur (AMPA/KA, NMDA)
GABAA
DA DA
DA
DA
?
DA
VP
N. Accumbens
DOI
GABA
GABA
GABA
Pyr
Atypical
antipsychotics
Fig. 4 Schematic representation of the direct and indirect connectivity
between the medial prefrontal cortex (mPFC) and ventral tegmental
area (VTA). The dotted frame marks the VTA, with known inputs from
the mPFC onto dopamine (DA) and GABAergic neurones according to
Carr and Sesack (2000a) (local GABA ﬁ DA inputs within the VTA
are not shown). Inhibitory GABAergic afferents from ventral pallidum
(VP) and excitatory [glutamate, acetylcholine (ACh)] afferents from the
pedunculopontine tegmentum (PPTg) are not shown to synapse on
DA or GABAergic neurones in the VTA. The electrical or pharmaco-
logical (bicuculline) activation of the mPFC output enhanced DA re-
lease in the VTA. Likewise, the selective activation of 5-HT2A
receptors in the mPFC by local DOI application increased DA cell
activity and DA release in the VTA and mPFC, an action mimicked by
systemic DOI administration. The prefrontal facilitation of VTA DA
neurones may be direct, via an excitatory pathway to VTA DA neu-
rones projecting to the prefrontal cortex (PFC) and unidentified areas
(but not nucleus accumbens; Carr and Sesack 2000a), or indirect. The
latter pathways may include the above inputs from VP and PPTg.
Atypical antipsychotics may act on various receptors present in the
PFC, such as 5-HT2A or 5-HT2C, to modulate DA cell transmission via
these pathways. Likewise, the colocalization of 5-HT1A with 5-HT2A
receptors in the PFC (Amargo´s-Bosch et al. 2004) and the evidence
that prefrontal DA release is modulated by atypical antipsychotic drugs
via 5-HT1A receptors (Rollema et al. 1997; Ichikawa et al. 2001b)
suggest that the latter receptors in the PFC may also be involved. Glu,
glutamate; iGluR, ionotropic glutamate receptors; KA, kainate; Pyr,
pyramidol neurons.
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The similarity between the effect of the local and systemic
DOI administration suggests that the dense population of
5-HT2A receptors in the mPFC (Pompeiano et al. 1994;
Amargo´s-Bosch et al. 2004; Santana et al. 2004) plays amajor
role in the modulation of DA neurones, notwithstanding the
presence of a smaller receptor subset in the VTA (Nocjar et al.
2002). Indeed, the parallel increase in pyramidal (Puig et al.
2003) and DA neurone activity (this study) produced by the
same doses of DOI suggests a close relationship between both
effects. As discussed above for the effect of electrical
stimulation, it is unclear whether the action of DOI is mediated
by direct or indirect inputs to the VTA (Fig. 4).
The cancellation of the effect of DOI on DA neurone
activity and on prefrontal DA release by M100907 suggests
that it was due to interaction with 5-HT2A receptors.
However, a limitation of the present study is that the local
and distal effects of DOI on DA release were reversed by the
5-HT2A/2C antagonist ritanserin. This was a necessity due to
the limited availability of M100907, which is not commer-
cially available. It is unlikely that 5-HT2C receptors partici-
pate in the ritanserin reversal as: (1) the systemic effect of
DOI was reversed by M100907; (2) DOI was applied in an
mPFC area very rich in pyramidal neurones containing
5-HT2A receptors (Santana et al. 2004) and (3) 5-HT2C
receptor activation inhibits, rather than enhances, DA
transmission (Gobert et al. 2000; Di Matteo et al. 2001;
De Deurwaerdere et al. 2004), which is in keeping with the
presence of 5-HT2C receptors in GABAergic interneurones in
the PFC (Liu et al. 2004). However, DOI is a potent 5-HT2C
receptor agonist and the stimulatory effect of 5-HT2C
receptors on DA transmission has been observed after
systemic drug administration. Therefore, we cannot rule out
that the stimulation of 5-HT2C receptors in the mPFC can
also contribute to the increase in DA cell activity and DA
release produced by DOI.
The putative mechanism by which DOI may modulate
DA neurone activity and somatodendritic and terminal DA
release is depicted in Fig. 4. Taking into account previous
data together with the present results obtained with the
local application of DOI in the mPFC, we suggest that
the activation of 5-HT2A receptors in the mPFC enhanced
the excitatory cortical output to midbrain, resulting in an
increased activity of VTA DA neurones which subse-
quently resulted in an increased DA release. A similar
mechanism has previously been reported for raphe 5-HT
neurones (Martı´n-Ruiz et al. 2001). Additionally, given the
presence of a small subset of 5-HT2A receptors in mPFC
axons possibly on catecholaminergic terminals (Miner et al.
2003), DOI might also modulate DA release in a local
manner.
In summary, the present results support the view that
5-HT2A receptors in the mPFC modulate distally the activity
of DA neurones in the VTA. The activation of such receptors
markedly increases DA neurone activity and DA release in
the mesocortical pathway but it is still unknown whether this
excitatory inﬂuence is exerted via direct or indirect inputs to
the VTA. Given the widespread inﬂuence of prefrontal
5-HT2A receptors on VTA DA neurones (of which a majority
projects to limbic areas) we suggest that atypical antipsy-
chotic drugs may modulate the activity of ascending DA
pathways by a cortically based action. Hence, the blockade
of 5-HT2A receptors in the PFC may attenuate a putative DA
overactivity in schizophrenia. This effect would reduce DA
cell activity and DA release in target areas without the
massive blockade of post-synaptic D2 receptors induced by
classical neuroleptics, which is responsible for the severe
side-effects of these compounds.
Acknowledgements
This work was supported by grant SAF 2004-05525. Financial
support from Lilly and support from the CIEN network (IDIBAPS-
ISCIII RTIC C03/06) and Generalitat de Catalunya 2001-SGR00355
are also acknowledged. PC and AB are recipients of a Ramo´n y
Cajal contract from the Ministry of Science and Technology. MCS
was the recipient of a post-doctoral fellowship from Fundacio´n
Carolina. LD-M is the recipient of a pre-doctoral fellowship from
IDIBAPS. We thank Leticia Campa and Judith Ballart for skilful
technical assistance.
References
Abi-Dargham A., Rodenhiser J., Printz D. et al. (2000) Increased
baseline occupancy of D2 receptors by dopamine in schizophrenia.
Proc. Natl Acad. Sci. USA 97, 8104–8109.
Adell A. and Artigas F. (2004) The somatodendritic release of dopamine
in the ventral tegmental area and its regulation by afferent trans-
mitter systems. Neurosci. Biobehav. Rev. 28, 415–431.
Amargo´s-Bosch M., Bortolozzi A., Puig M. V., Serrats J., Adell A.,
Celada P., Toth M., Mengod G. and Artigas F. (2004) Co-expres-
sion and in vivo interaction of 5-HT1A and -HT2A receptors in
pyramidal neurons of prefrontal cortex. Cereb. Cortex 14, 281–
299.
Andreasen N. C., O’Leary D. S., Flaum M., Nopoulos P., Watkins G. L.,
Boles Ponto L. L. and Hichwa R. D. (1997) Hypofrontality in
schizophrenia: distributed dysfunctional circuits in neuroleptic-
naive patients. Lancet 349, 1730–1734.
Araneda R. and Andrade R. (1991) 5-HT2 and 5-HT1A receptors mediate
opposing responses on membrane excitability in rat association
cortex. Neuroscience 40, 399–412.
Bertolino A., Esposito G., Callicott J. H., Mattay V. S., Van Horn J. D.,
Frank J. A., Berman K. F. and Weinberger D. R. (2000) Speciﬁc
relationship between prefrontal neuronal N-acetylaspartate and
activation of the working memory cortical network in schizo-
phrenia. Am. J. Psychiat. 157, 26–33.
Burnet P. W., Eastwood S. L., Lacey K. and Harrison P. J. (1995) The
distribution of 5-HT1A and 5-HT2A receptor mRNA in human
brain. Brain Res. 676, 157–168.
Carlsson A. (1988) The current status of the dopamine hypothesis of
schizophrenia. Neuropsychopharmacology 1, 179–186.
Carr D. B. and Sesack S. R. (2000a) Projections from the rat prefrontal
cortex to the ventral tegmental area: target speciﬁcity in the syn-
aptic associations with mesoaccumbens and mesocortical neurons.
J. Neurosci. 20, 3864–3873.
5-HT2A control of dopamine activity 1605
 2005 International Society for Neurochemistry, J. Neurochem. (2005) 95, 1597–1607
Carr D. B. and Sesack S. R. (2000b) GABA-containing neurons in the
rat ventral tegmental area project to the prefrontal cortex. Synapse
38, 114–123.
Celada P., Paladini C. A. and Tepper J. M. (1999) GABAergic control
of rat substantia nigra dopaminergic neurons: role of globus
pallidus and substantia nigra pars reticulata. Neuroscience 89,
813–825.
Celada P., Puig M. V., Casanovas J. M., Guillazo G. and Artigas F.
(2001) Control of dorsal raphe serotonergic neurons by the medial
prefrontal cortex: Involvement of serotonin-1A, GABA A, and
glutamate receptors. J. Neurosci. 21, 9917–9929.
Chergui K., Suaud-Chagny M. F. and Gonon F. (1994) Non linear
relationship between impulse ﬂow, dopamine release and dopamine
elimination in the rat brain in vivo. Neuroscience 62, 641–645.
Creese I., Burt D. R. and Snyder S. H. (1976) Dopamine receptor
binding predicts clinical and pharmacological potencies of anti-
schizophrenic drugs. Science 192, 481–483.
De Deurwaerdere P., Navailles S., Berg K. A., Clarke W. P. and
Spampinato U. (2004) Constitutive activity of the 5-HT2C receptor
inhibits in vivo dopamine release in the rat striatum and nucleus
accumbens. J. Neurosci. 24, 3235–3241.
Devoto P., Flore G., Pira L., Diana M. and Gessa L. (2002) Co-release of
noradrenaline and dopamine in the prefrontal cortex after acute
morphine and during morphine withdrawal. Psychopharmacology
(Berl.) 160, 220–224.
Di Matteo V., De Blasi A., Di Giulio C. and Esposito E. (2001) Role of
5-HT2C receptors in the control of central dopamine function.
Trends Pharmacol. Sci. 22, 229–232.
Fa M., Mereu G., Ghiglieri V., Meloni A., Salis P. and Gessa G. L.
(2003) Electrophysiological and pharmacological characteristics of
nigral dopaminergic neurons in the conscious, head-restrained rat.
Synapse 48, 1–9.
Ferre´ S., Corte´s R. and Artigas F. (1994) Dopaminergic regulation of the
serotonergic raphe-striatal pathway: microdialysis studies in freely
moving rats. J. Neurosci. 14, 4839–4846.
Floresco S. B., West A. R., Ash B., Moore H. and Grace A. A. (2003)
Afferent modulation of dopamine neuron ﬁring differentially
regulates tonic and phasic dopamine transmission. Nat. Neurosci.
6, 968–973.
Fuster J. M. (2001) The prefrontal cortex ) an update: time is of the
essence. Neuron 30, 319–333.
Gariano R. F. and Groves P. M. (1988) Burst ﬁring induced in midbrain
dopamine neurons by stimulation of the medial prefrontal and
anterior cingulate cortices. Brain Res. 462, 194–198.
Glowinski J., Tassin J. P. and Thierry A. M. (1984) The mesocortico-
prefrontal dopaminergic neurons. Trends Neurosci. 84, 415–418.
Gobert A. and Millan M. J. (1999) Serotonin 5-HT2A receptor activation
enhances dialysate levels of dopamine and noradrenaline, but not
5-HT, in the frontal cortex of freely-moving rats. Neuropharma-
cology 38, 315–317.
Gobert A., Rivet J. M., Lejeune F., Newman-Tancredi A., Adhumeau-
Auclair A., Nicolas J. P., Cistarelli L., Melon C. and Millan M. J.
(2000) 5-HT2C receptors tonically suppress the activity of meso-
cortical dopaminergic and adrenergic, but not serotonergic, path-
ways: a combined dialysis and electrophysiological analysis in the
rat. Synapse 36, 205–221.
Grace A. A. and Bunney B. S. (1984) The control of ﬁring pattern in
nigral dopamine neurons: burst ﬁring. J. Neurosci. 4, 2877–2890.
Ichikawa J., Dai J. and Meltzer H. Y. (2001a) DOI, a 5-HT2A/2C receptor
agonist, attenuates clozapine-induced cortical dopamine release.
Brain Res. 907, 151–155.
Ichikawa J., Ishii H., Bonaccorso S., Fowler W. L., O’Laughlin I. A. and
Meltzer H. Y. (2001b) 5-HT2A and D2 receptor blockade increases
cortical DA release via 5-HT1A receptor activation: a possible
mechanism of atypical antipsychotic-induced cortical dopamine
release. J. Neurochem. 76, 1521–1531.
Jackson M. E., Frost A. S. and Moghaddam B. (2001) Stimulation of
prefrontal cortex at physiologically relevant frequencies inhibits
dopamine release in the nucleus accumbens. J. Neurochem. 78,
920–923.
Laruelle M., Abi-Dargham A., van Dyck C. H. et al. (1996) Single
photon emission computerized tomography imaging of amphet-
amine-induced dopamine release in drug-free schizophrenic sub-
jects. Proc. Natl Acad. Sci. USA 93, 9235–9240.
Liu S., Bubar M. J., Herin D. V. and Cunningham K. A. (2004)
Localization of the Serotonin 5-HT2C Receptor in the Rat
Prefrontal Cortex. Program no. 578.13. Abstract Viewer/Itinerary
Planner. Society for Neuroscience, Washington, DC.
Lo´pez-Gime´nez J. F., Vilaro´ M. T., Palacios J. M. and Mengod G. (1998)
[3H] MDL100,907 labels 5-HT2A serotonin receptors selectively in
primate brain. Neuropharmacology 37, 1147–1158.
Martı´n-Ruiz R., Puig M. V., Celada P., Shapiro D. A., Roth B. L.,
Mengod G. and Artigas F. (2001) Control of serotonergic function
in medial prefrontal cortex by 5-HT2A receptors through a glu-
tamate-dependent mechanism. J. Neurosci. 21, 9856–9866.
Mathe´ J. M., Nomikos G. G., Blakeman K. H. and Svensson T. H.
(1999) Differential actions of dizocilpine (MK-801) on the meso-
limbic and mesocortical dopamine systems: role of neuronal
activity. Neuropharmacology 38, 121–128.
Meltzer H. Y. (1999) The role of serotonin in antipsychotic drug action.
Neuropsychopharmacology 21, S106–S115.
Minabe Y., Hashimoto K., Watanabe K. I. and Ashby C. R. Jr (2001)
Acute and repeated administrations of the selective 5-HT2A
receptor antagonist M100907 signiﬁcantly alter the activity of
midbrain dopamine neurons: an in vivo electrophysiological study.
Synapse 40, 102–112.
Miner L. A., Backstrom J. R., Sanders-Bush E. and Sesack S. R. (2003)
Ultrastructural localization of 5-HT2A receptors in the middle layers
of the rat prelimbic prefrontal cortex. Neuroscience 116, 107–117.
Murase S., Grenhoff J., Chouvet G., Gonon F. G. and Svensson T. H.
(1993) Prefrontal cortex regulates burst ﬁring and transmitter
release in rat mesolimbic dopamine neurons studied in vivo.
Neurosci. Lett. 157, 53–56.
Nocjar C., Roth B. L. and Pehek E. A. (2002) Localization of 5-HT2A
receptors on dopamine cells in subnuclei of the midbrain A10 cell
group. Neuroscience 111, 163–176.
Nyberg S., Nilsson U., Okubo Y., Halldin C. and Farde L. (1998)
Implications of brain imaging for the management of schizophre-
nia. Int. Clin. Psychopharmacol. 13, S15–S20.
Omelchenko N. and Sesack S. R. (2005) Laterodorsal tegmental pro-
jections to identiﬁed cell populations in the rat ventral tegmental
area. J. Comp. Neurol. 483, 217–235.
Overton P. G. and Clark D. (1997) Burst ﬁring in midbrain dopaminergic
neurons. Brain Res. Rev. 25, 312–334.
Paxinos G. and Watson C. (1998) The Rat Brain in Stereotaxic
Coordinates. Academic Press, Sydney.
Pehek E. A., McFarlane H. G., Maguschak K., Price B. and Pluto C. P.
(2001) M100,907, a selective 5-HT2A antagonist, attenuates
dopamine release in the rat medial prefrontal cortex. Brain Res.
888, 51–59.
Pompeiano M., Palacios J. M. and Mengod G. (1994) Distribution of the
serotonin 5-HT2 receptor family mRNAs: comparison between
5-HT2A and 5-HT2C receptors. Mol. Brain Res. 23, 163–178.
Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdere P.,
Caccia S., Esposito E. and Spampinato U. (2002) 5-HT2A and
5-HT2C/2B receptor subtypes modulate dopamine release induced in
vivo by amphetamine and morphine in both the rat nucleus
accumbens and striatum. Neuropsychopharmacology 26, 311–324.
1606 A. Bortolozzi et al.
 2005 International Society for Neurochemistry, J. Neurochem. (2005) 95, 1597–1607
Puig M. V., Celada P., Dı´az-Mataix L. and Artigas F. (2003) In vivo
modulation of the activity of pyramidal neurons in the rat medial
prefrontal cortex by 5-HT2A receptors: relationship to thalamo-
cortical afferents. Cereb. Cortex 13, 870–882.
Robbins T. W. (2000) Chemical neuromodulation of frontal-executive
functions in humans and other animals. Exp. Brain Res. 133, 130–
138.
Rollema H., Lu Y., Schimdt A. W. and Zorn S. H. (1997) Clozapine
increases dopamine release in prefrontal cortex by 5-HT1A receptor
activation. Eur. J. Pharmacol. 338, R3–R5.
Roth B. L., Shefﬂer D. and Potkin S. G. (2003) Atypical antipsychotic
drug actions: unitary or multiple mechanisms for ‘atypicality’?
Clin. Neurosci. Res. 3, 108–117.
Santana N., Bortolozzi A., Serrats J., Mengod G. and Artigas F. (2004)
Expression of 5-HT1A and 5-HT2A receptors in pyramidal and
GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 14,
1100–1109.
Schultz W. (2004) Neural coding of basic reward terms of animal
learning theory, game theory, microeconomics and behavioural
ecology. Curr. Opin. Neurobiol. 14, 139–147.
Seeman P. and Lee T. (1975) Antipsychotic drugs: direct correlation
between clinical potency and presynaptic action on dopamine
neurons. Science 188, 1217–1219.
Sesack S. R., Carr D. B., Omelchenko N. and Pinto A. (2003) Ana-
tomical substrates for glutamate–dopamine interactions: evidence
for speciﬁcity of connections and extrasynaptic actions. Ann. NY
Acad. Sci. 1003, 36–52.
Taber M. T. and Fibiger H. C. (1995) Electrical stimulation of the pre-
frontal cortex increases dopamine release in nucleus accumbens of
the rat: modulation by metabotropic glutamate receptors. J. Neu-
rosci. 15, 3896–3904.
Tanaka E. and North R. A. (1993) Actions of 5-HT on neurons of the rat
cingulate cortex. J. Neurophysiol. 69, 1749–1757.
Thierry A. M., Deniau J. M. and Feger J. (1979) Effects of stimulation
of the frontal cortex on identiﬁed output VMT cells in the rat.
Neurosci. Lett. 15, 102–107.
Thierry A. M., Chevalier G., Ferron A. and Glowinski J. (1983) Dien-
cephalic and mesencephalic efferents of the medial prefrontal
cortex in the rat: electrophysiological evidence for the existence of
branched axons. Exp. Brain Res. 50, 275–282.
Tong Z. Y., Overton P. G. and Clark D. (1996) Stimulation of the pre-
frontal cortex in the rat induces patterns of activity in midbrain
dopaminergic neurons which resemble natural burst events. Syn-
apse 22, 195–208.
Tong Z. Y., Overton P. G., Martinez-Cue C. and Clark D. (1998) Do non-
dopaminergic neurons in the ventral tegmental area play a role in the
responses elicited in A10 dopaminergic neurons by electrical stimu-
lation of the prefrontal cortex? Exp. Brain Res. 118, 466–476.
Tzschentke T. M. and Schmidt W. J. (2000) Functional relationship
among medial prefrontal cortex, nucleus accumbens, and ventral
tegmental area in locomotion and reward. Crit. Rev. Neurobiol. 14,
131–142.
Weinberger D. R., Aloia M. S., Goldberg T. E. and Berman K. F. (1994)
The frontal lobes and schizophrenia. J. Neuropsychiat. Clin.
Neurosci. 6, 419–427.
Williams G. V. and Goldman-Rakic P. S. (1995) Modulation of memory
ﬁelds by dopamine D1 receptors in prefrontal cortex. Nature 376,
572–575.
5-HT2A control of dopamine activity 1607
 2005 International Society for Neurochemistry, J. Neurochem. (2005) 95, 1597–1607
